Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years After Successful Interferon-Based Hepatitis C Virus Treatment

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2015 Nov 17

PMID 26568966

Citations 5

Authors

Paul Ravi Waldron

Mark Holodniy

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory gene expression in peripheral blood mononuclear cells (PBMCs) is altered in chronic Hepatitis C Virus (HCV) infection. Duration of changes after pegylated interferon- (peg-IFN-) based HCV treatment is unclear.

Methods: PBMC mRNA expression of 184 inflammatory response genes was analyzed (nCounter GX Human Inflammation Kit, Nanostring) from peg-IFN treatment nonresponders (NR, n = 18), sustained virologic responders (SVR, n = 22), and spontaneous clearers (SC, n = 15). Logistic regression was used for comparison.

Results: Median time from last treatment was 2 and 2.7 years in SVR and NR, respectively (p = NS). Mean mRNA counts were significantly different for 42 and 29 genes comparing SVR to SC patients and NR to SC, respectively, and no genes comparing SVR to NR. Differential expression of 24 genes was significantly different in both SVR and NR groups compared to SC. Among these 24 acute and chronic inflammatory cascade genes, significant upregulation was noted for proinflammatory transcription regulators Fos, CEBPB, and MyD88 in SVR and NR compared to SC. HDAC4 was significantly downregulated in SVR and NR compared to the SC group.

Conclusions: PBMC inflammatory gene expression patterns in SVR resemble NR more than SC patients. A generalized inflammatory response persists in PBMCs long after successful peg-IFN treatment for HCV infection.

Citing Articles

Differentiating between liver diseases by applying multiclass machine learning approaches to transcriptomics of liver tissue or blood-based samples.

Listopad S, Magnan C, Asghar A, Stolz A, Tayek J, Liu Z JHEP Rep. 2022; 4(10):100560.

PMID: 36119721 PMC: 9472076. DOI: 10.1016/j.jhepr.2022.100560.

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients.

Brochado O, Martinez I, Berenguer J, Medrano L, Gonzalez-Garcia J, Jimenez-Sousa M J Biomed Sci. 2021; 28(1):23.

PMID: 33785040 PMC: 8010945. DOI: 10.1186/s12929-021-00718-6.

Soil Viruses Are Underexplored Players in Ecosystem Carbon Processing.

Trubl G, Jang H, Roux S, Emerson J, Solonenko N, Vik D mSystems. 2018; 3(5).

PMID: 30320215 PMC: 6172770. DOI: 10.1128/mSystems.00076-18.

Analysis of TLR7, SOCS1 and ISG15 immune genes expression in the peripheral blood of responder and non-responder patients with chronic Hepatitis C.

Dowran R, Sarvari J, Moattari A, Fattahi M, Ramezani A, Hosseini S Gastroenterol Hepatol Bed Bench. 2018; 10(4):272-277.

PMID: 29379591 PMC: 5758734.

Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma.

Hosry J, Mahale P, Turturro F, Miranda R, Economides M, Granwehr B Int J Cancer. 2016; 139(11):2519-28.

PMID: 27501007 PMC: 5028297. DOI: 10.1002/ijc.30372.

References

Zaghloul H, El-Sherbiny W . Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest. 2010; 39(3):284-91. DOI: 10.3109/08820131003605820. View

Zayed R, Rushdy E, Saleh D . Detection of HCV RNA in the peripheral blood mononuclear cells of serum HCV RNA-negative Egyptian patients under interferon treatment. Am J Med Sci. 2010; 340(6):435-8. DOI: 10.1097/MAJ.0b013e3181ec435e. View

Zimmermann H, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C . Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One. 2011; 6(6):e21381. PMC: 3120868. DOI: 10.1371/journal.pone.0021381. View

Mohamad H, Fath El-Bab H, Kamal A . HCV RNA in serum and peripheral blood mononuclear cells after successful interferon therapy. Hepatogastroenterology. 2011; 58(107-108):932-6. View

Ghany M, Nelson D, Strader D, Thomas D, Seeff L . An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(4):1433-44. PMC: 3229841. DOI: 10.1002/hep.24641. View

Chak E, Talal A, Sherman K, Schiff E, Saab S . Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011; 31(8):1090-101. DOI: 10.1111/j.1478-3231.2011.02494.x. View

Radkowski M, Gallegos-Orozco J, Jablonska J, Colby T, Walewska-Zielecka B, Kubicka J . Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2004; 41(1):106-14. DOI: 10.1002/hep.20518. View

Hess J, Angel P, Schorpp-Kistner M . AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 2004; 117(Pt 25):5965-73. DOI: 10.1242/jcs.01589. View

Kenny-Walsh E . Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999; 340(16):1228-33. DOI: 10.1056/NEJM199904223401602. View

10.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

11.

Fitzgerald K, Palsson-McDermott E, Bowie A, Jefferies C, Mansell A, Brady G . Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature. 2001; 413(6851):78-83. DOI: 10.1038/35092578. View

12.

Thomas D, Astemborski J, RAI R, Anania F, Schaeffer M, Galai N . The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000; 284(4):450-6. DOI: 10.1001/jama.284.4.450. View

13.

Casado J, Esteban M, Banon S, Moreno A, Perez-Elias M, Mateos M . Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response. Dig Dis Sci. 2015; 60(11):3473-81. DOI: 10.1007/s10620-015-3773-y. View

14.

Radkowski M, Opoka-Kegler J, Caraballo Cortes K, Bukowska-Osko I, Perlejewski K, Pawelczyk A . Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin. J Gen Virol. 2014; 95(Pt 9):2004-2009. DOI: 10.1099/vir.0.064709-0. View

15.

Saraiva M, OGarra A . The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010; 10(3):170-81. DOI: 10.1038/nri2711. View

16.

Thomas D, Thio C, Martin M, Qi Y, Ge D, OhUigin C . Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798-801. PMC: 3172006. DOI: 10.1038/nature08463. View

17.

Pham T, Mercer S, Michalak T . Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat. 2009; 16(8):547-56. DOI: 10.1111/j.1365-2893.2009.01092.x. View

18.

Ghany M, Strader D, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4):1335-74. PMC: 7477893. DOI: 10.1002/hep.22759. View

19.

Bernardin F, Tobler L, Walsh I, Williams J, Busch M, Delwart E . Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology. 2008; 47(5):1446-52. DOI: 10.1002/hep.22184. View

20.

Glenisson W, Castronovo V, Waltregny D . Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta. 2007; 1773(10):1572-82. DOI: 10.1016/j.bbamcr.2007.05.016. View